Article
Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors
2023-07-14
Abstract excerpt
<title>Abstract</title> <p>The clinical development of farnesyltransferase inhibitors (FTI) for <italic>HRAS</italic>-mutant tumors showed mixed responses dependent on cancer type. Co-occurring mutations may affect response. We aimed to uncover cooperative genetic events specific to <italic>HRAS</italic>-mutant tumors and study their effect on FTI sensitivity. Using targeted sequencing data from MSK-IMPACT and DF...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 81ff3949-6fdc-5972-8fa1-931ace0da04a
- DOI
- 10.21203/rs.3.rs-3154719/v1
